NASDAQ:IDYA - IDEAYA Biosciences Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $33.00
  • Forecasted Upside: 50.48 %
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$21.93
▼ -0.32 (-1.44%)

This chart shows the closing price for IDYA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New IDEAYA Biosciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IDYA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IDYA

Analyst Price Target is $33.00
▲ +50.48% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for IDEAYA Biosciences in the last 3 months. The average price target is $33.00, with a high forecast of $38.00 and a low forecast of $28.00. The average price target represents a 50.48% upside from the last price of $21.93.

This chart shows the closing price for IDYA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 6 contributing investment analysts is to buy stock in IDEAYA Biosciences. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/31/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/30/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/29/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/27/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/25/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/25/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/24/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/24/2021

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/11/2021HC WainwrightLower Price TargetBuy$35.00 ➝ $34.00High
4/22/2021Roth CapitalBoost Price TargetPositive ➝ Buy$31.00 ➝ $38.00Low
4/19/2021HC WainwrightBoost Price TargetPositive ➝ Buy$29.00 ➝ $35.00High
4/16/2021Roth CapitalBoost Price Target$23.00 ➝ $31.00Low
4/16/2021JPMorgan Chase & Co.Boost Price TargetOverweight$28.00 ➝ $34.00High
3/24/2021CitigroupBoost Price Target$20.00 ➝ $33.00Medium
3/15/2021WedbushBoost Price TargetOutperform$25.00 ➝ $32.00Low
3/11/2021GuggenheimInitiated CoverageBuy$32.00High
10/7/2020Northland SecuritiesReiterated RatingBuy$28.00High
10/6/2020WedbushInitiated CoverageOutperform$21.00High
9/28/2020Northland SecuritiesReiterated RatingBuy$28.00Medium
9/1/2020Northland SecuritiesInitiated CoverageOutperform$28.00High
7/13/2020JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$28.00High
6/17/2020HC WainwrightBoost Price TargetBuy$13.00 ➝ $22.00High
6/16/2020OppenheimerBoost Price TargetOutperform$17.00 ➝ $25.00Low
6/8/2020HC WainwrightReiterated RatingBuy$13.00Low
5/12/2020OppenheimerInitiated CoverageBuy$17.00High
4/6/2020HC WainwrightInitiated CoverageBuy$13.00High
3/13/2020Roth CapitalInitiated CoverageBuy$12.00Medium
10/17/2019OppenheimerInitiated CoverageOutperform$17.00High
9/9/2019Robert W. BairdInitiated CoverageOutperform$30.00High
6/17/2019Jefferies Financial GroupInitiated CoverageBuy$14.00Low
6/17/2019CitigroupInitiated CoverageBuy$20.00Low
6/17/2019JPMorgan Chase & Co.Initiated CoverageNeutral$15.00Low
(Data available from 7/25/2016 forward)
IDEAYA Biosciences logo
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's product candidate is IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting IDE397, a methionine adenosyltransferase 2a inhibitor for patients with solid tumors having MTAP deletions; PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in high microsatellite instability tumors. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase I/II study in metastatic uveal melanoma, skin melanoma, and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $21.93
Low: $21.09
High: $22.63

50 Day Range

MA: $20.68
Low: $17.26
High: $22.74

52 Week Range

Now: $21.93
Low: $10.90
High: $24.92

Volume

471,831 shs

Average Volume

393,960 shs

Market Capitalization

$721.72 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.92

Frequently Asked Questions

What sell-side analysts currently cover shares of IDEAYA Biosciences?

The following Wall Street research analysts have issued reports on IDEAYA Biosciences in the last year: Citigroup Inc., Guggenheim, HC Wainwright, JPMorgan Chase & Co., Northland Securities, Roth Capital, Wedbush, and Zacks Investment Research.
View the latest analyst ratings for IDYA.

What is the current price target for IDEAYA Biosciences?

7 Wall Street analysts have set twelve-month price targets for IDEAYA Biosciences in the last year. Their average twelve-month price target is $33.00, suggesting a possible upside of 50.5%. Roth Capital has the highest price target set, predicting IDYA will reach $38.00 in the next twelve months. Northland Securities has the lowest price target set, forecasting a price of $28.00 for IDEAYA Biosciences in the next year.
View the latest price targets for IDYA.

What is the current consensus analyst rating for IDEAYA Biosciences?

IDEAYA Biosciences currently has 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe IDYA will outperform the market and that investors should add to their positions of IDEAYA Biosciences.
View the latest ratings for IDYA.

What other companies compete with IDEAYA Biosciences?

How do I contact IDEAYA Biosciences' investor relations team?

IDEAYA Biosciences' physical mailing address is 7000 SHORELINE COURT SUITE 350, SOUTH SAN FRANCISCO CA, 94080. The company's listed phone number is (650) 443-6209 and its investor relations email address is [email protected] The official website for IDEAYA Biosciences is www.ideayabio.com.